New Edition of Cancer Care’s Helping Hand Available

Publication
Article
OncologyONCOLOGY Vol 16 No 8
Volume 16
Issue 8

Cancer Care has published the fourth edition of its handbook-A Helping Hand: The Resource Guide for People With Cancer. The 148-page booklet contains listings and descriptions of organizations that offer a wide variety of services, support, and information for people with cancer. In general, the booklet shows cancer patients what types of help are available to them and where they can find it, both nationally and regionally. Listings include cancer centers, commercial services that offer products of particular interest to people with cancer (such as wigs and prostheses), state pharmaceutical assistance programs, pharmaceutical manufacturers’ indigent drug programs, and useful tips on what to ask when contacting such services.

Cancer Care has published the fourth edition of itshandbook—A Helping Hand: The Resource Guide for People With Cancer. The148-page booklet contains listings and descriptions of organizations that offera wide variety of services, support, and information for people with cancer. Ingeneral, the booklet shows cancer patients what types of help are available tothem and where they can find it, both nationally and regionally. Listingsinclude cancer centers, commercial services that offer products of particularinterest to people with cancer (such as wigs and prostheses), statepharmaceutical assistance programs, pharmaceutical manufacturers’ indigentdrug programs, and useful tips on what to ask when contacting such services.

The booklet can be ordered by calling 1-800-813-4673 and is available as asearchable database on Cancer Care’s website, www.cancercare.org.

Articles in this issue
Irinotecan and Other Agents in New Combinations and Other Tumor Types
New Edition of Cancer Care’s Helping Hand Available
Handbook of Gynecologic Oncology
First Study to Show Chemotherapy Extends Survival of Advanced Prostate Cancer Patients
Clinton/Reid Bill Would Boost Cancer Tracking at CDC
Novartis Seeks to Market Gleevec for First-Line Use in Chronic Myeloid Leukemia
Docetaxel Improves Survival in Node-Positive Early-Stage Breast Cancer Patients
Docetaxel/Platinum Combination Provides Quality-of-Life Advantage Over Vinorelbine/Cisplatin in Advanced Lung Cancer
House Restores Some Medicare Physician Pay Cuts
Medicare Proposes Calendar 2003 Pay Rate
Mathematical Modeling for Breast Cancer Risk Assessment
What Is the Optimal Therapy for Childhood AML?
Current Management of Depression in Cancer Patients
Current Clinical Trials of the Cancer Trials Support Unit (CTSU), an NCI Pilot Program
Mathematical Modeling for Breast Cancer Risk Assessment
Recent Videos
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.

A Decline in the US Oncology Workforce: What Will the Next Decade Bring?

Julie M. Vose, MD, MBA
December 2nd 2025
Article

Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

ONCOLOGY Editorial Advisory Board Member Dies from Glioblastoma

ONCOLOGY Editorial Advisory Board Member Dies from Glioblastoma

Ariana Pelosci
December 1st 2025
Article

Edward Chu, MD, a member of the gastrointestinal editorial advisory board, died of glioblastoma in November.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

The developers plan to submit a new drug application to regulatory authorities for JS001sc for the treatment of first-line non-squamous NSCLC.

Subcutaneous Toripalimab Meets Primary End Points in Nonsquamous NSCLC

Roman Fabbricatore
November 30th 2025
Article

The developers plan to submit a new drug application to regulatory authorities for JS001sc for the treatment of first-line nonsquamous NSCLC.

According to Daniel Peters, MD, the recent FDA approvals of revumenib and ziftomenib in AML are some of the most exciting developments in the field.

The Paradigm of AML Care: What’s New and What’s Changing

Tim Cortese
November 30th 2025
Article

According to Daniel Peters, MD, the recent FDA approvals of revumenib and ziftomenib in AML are some of the most exciting developments in the field.